Table of Contents Table of Contents
Previous Page  380 / 1082 Next Page
Information
Show Menu
Previous Page 380 / 1082 Next Page
Page Background

S365

ESTRO 36 2017

_______________________________________________________________________________________________

we have applied a multiplex magnetic bead panel

(Luminex

®

) to explore associations between serum

proteins and treatment outcome in patients with locally

advanced rectal cancer.

Material and Methods

Serum samples from 22 rectal cancer patients were

collected at the time of diagnosis. All patients underwent

neoadjuvant long-course chemoradiotherapy (CRT),

according to current national guidelines. Surgery was

performed 6-8 weeks after completion of CRT and five

patients underwent adjuvant chemotherapy. CRT

responses were evaluated by ypTN staging and tumour

regression grade (TRG) (College of American Pathologists

system) scoring. The median follow-up time was 21

months (range 1-34). Using multiplex magnetic bead

technology (Luminex

®

, R&D systems), a manually selected

panel of 86 proteins involved in angiogenesis, hypoxia and

metastasis was applied to analyse serum samples.

Associations were explored using two-sided Student’s t-

tests, with p-values < 0.05 considered statistically

significant. The STRING (Search Tool for the Retrieval of

Interacting Genes/Proteins) database (

string-db.org)

was

used to predict interaction networks. Survival differences

were assessed by the log-rank test and visualised by the

Kaplan-Meier method.

Results

Significant associations between several serum proteins

and TNM, ypTN, TRG and progression-free survival (PFS)

were detected. STRING analysis identified that a majority

of these proteins were involved in the PI3K-Akt signaling

pathway, and particularly angiopoietin-2 (ANGPT2) and

platelet-derived growth factor subunit B (PDGFB) were

associated to multiple end-points. By combining ANGPT2

and PDGFB, high levels were associated with both poor

histopathologic outcome (ypT3-4 versus ypT0-2: p=0.040;

TRG2-3 versus TRG1: p=0.015) (Table 1) and PFS (cut-off

8700 pg/ml, p-value 0.031), with all PFS events being

development of liver metastasis (Figure 1).

Table 1 ANGPT2 and PDGFB

Figure

1

Conclusion

Tumour angiogenesis is a major mechanism in sustained

tumour progression and the metastatic process. In the

current study, our main finding was that high serum levels

of the angiogenic factors ANGPT2 and PDGFB identified

patients with poor histopathologic response to

neoadjuvant CRT, who subsequently progressed rapidly to

metastatic disease. These results may point out an

escalating tumour aggressiveness paralleled by increasing

angiogenesis. The results were achieved in a small cohort

and require validation, but may represent an approach for

early selection of patients with an aggressive tumour

phenotype for intensified treatment strategies, perhaps

also with combinatory regimens targeting angiogenesis.

The results are currently being validated in an

independent patient cohort.

PO-0705 Work ability in Dutch rectal cancer patients

during the first year of treatment

A.M. Couwenberg

1

, M.P.W. Intven

1

, J.P.M. Burbach

1

, L.

Hupkens

2

, W.M.U. Van Grevenstein

3

, H.M. Verkooijen

4

1

UMC Utrecht, Radiotherapy, Utrecht, The Netherlands

2

Blik op Werk, Quality and research institute on

workability, Utrecht, The Netherlands

3

UMC Utrecht, Surgery, Utrecht, The Netherlands

4

UMC Utrecht, Imaging Division, Utrecht, The

Netherlands

Purpose or Objective

Rectal cancer treatment is associated with substantial

morbidity and decreased quality of life. The impact of

treatment on workability has hardly been studied. In this

study we evaluated workability in rectal cancer patients

during the first year of treatment.

Material and Methods

All working-aged rectal cancer patients (<67 years) within

the Dutch prospective colorectal cancer cohort referred

for radiotherapy at the UMC Utrecht between February

2013 and January 2016 were selected. Workability was

assessed with the Work Ability Index (WAI) Questionnaire

before start of treatment and at 3, 6 and 12 months. The

WAI score, ranging from 7 to 49, was calculated for

patients with paid employment at time of assessment and

who completed at least one questionnaire. Higher scores

reflect better workability. Workability was categorized in

poor (7-27), moderate (28-36), good (37-43) and excellent

(44-49). Results were stratified for treatment strategies

and compared with scores of the age-matched Dutch

reference population.

Results